CA
NZ
UK
AU
IND
US
● TNL Mediagene formed a special committee to weigh a possibleMergerand asset sales, putting the company in play.
● Tenon Medical posted record second-quarter revenue, its strongest quarterly sales performance to date.
● Curis priced a $5.6 million raise carrying an explicit going-concern warning, underscoring the company's thin financial cushion.
● Eloxx Pharmaceuticals returned to trading on the Nasdaq Capital Market, less than three years after being removed from the exchange.
● Ernexa Therapeutics is lining up a third-quarter IND filing for lead candidate ERNA-101, its first application to test the drug in humans.
● GRI Bio won FDAOrphan DrugDesignation for lung-fibrosis candidate GRI-0621, a meaningful regulatory milestone.
● The company simultaneously advanced an FDA meeting request tied to its solid-tumor T-cell engager program.
● Moleculin Biotech reported a 37% blinded remission rate in venetoclax-failed AML patients, a fresh interim look at its most important ongoing trial.
● Revelation Biosciences adopted a 10% stockholder rights plan, commonly called a poison pill, on July 10, 2026.
● Reviva Pharmaceuticals'Investmentcase rests almost entirely on one molecule: brilaroxazine, an experimental once-daily pill for schizophrenia.
Please wait processing your request...